Genic Co., Ltd.

KOSDAQ:A123330 Stock Report

Market Cap: ₩160.4b

Genic Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Genic.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Personal Products earnings growth31.8%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Analysis Article Feb 06

Genic Co., Ltd. (KOSDAQ:123330) Looks Just Right With A 42% Price Jump

Genic Co., Ltd. ( KOSDAQ:123330 ) shareholders would be excited to see that the share price has had a great month...
Analysis Article Dec 04

These 4 Measures Indicate That Genic (KOSDAQ:123330) Is Using Debt Safely

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
Analysis Article Nov 03

Under The Bonnet, Genic's (KOSDAQ:123330) Returns Look Impressive

If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. One common...
Analysis Article Jul 15

Does Genic (KOSDAQ:123330) Have A Healthy Balance Sheet?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article Jun 16

A Look At The Fair Value Of Genic Co., Ltd. (KOSDAQ:123330)

Key Insights Genic's estimated fair value is ₩42,934 based on 2 Stage Free Cash Flow to Equity Genic's ₩41,750 share...
Analysis Article May 26

After Leaping 37% Genic Co., Ltd. (KOSDAQ:123330) Shares Are Not Flying Under The Radar

Genic Co., Ltd. ( KOSDAQ:123330 ) shares have had a really impressive month, gaining 37% after a shaky period...
Analysis Article May 23

Genic (KOSDAQ:123330) Is Very Good At Capital Allocation

If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Amongst other...
Analysis Article Apr 09

Risks Still Elevated At These Prices As Genic Co., Ltd. (KOSDAQ:123330) Shares Dive 25%

To the annoyance of some shareholders, Genic Co., Ltd. ( KOSDAQ:123330 ) shares are down a considerable 25% in the last...
Analysis Article Mar 25

Genic's (KOSDAQ:123330) Earnings Aren't As Good As They Appear

Even though Genic Co., Ltd. ( KOSDAQ:123330 ) posted strong earnings recently, the stock hasn't reacted in a large way...
Analysis Article Jan 23

Genic (KOSDAQ:123330) Is Experiencing Growth In Returns On Capital

To find a multi-bagger stock, what are the underlying trends we should look for in a business? Ideally, a business will...
Analysis Article Dec 26

Is Genic (KOSDAQ:123330) Using Too Much Debt?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article Nov 29

Genic Co., Ltd.'s (KOSDAQ:123330) Popularity With Investors Under Threat As Stock Sinks 30%

The Genic Co., Ltd. ( KOSDAQ:123330 ) share price has softened a substantial 30% over the previous 30 days, handing...
Analysis Article Oct 10

There's Reason For Concern Over Genic Co., Ltd.'s (KOSDAQ:123330) Massive 34% Price Jump

Despite an already strong run, Genic Co., Ltd. ( KOSDAQ:123330 ) shares have been powering on, with a gain of 34% in...
Analysis Article Jul 27

Genic Co., Ltd.'s (KOSDAQ:123330) Share Price Not Quite Adding Up

There wouldn't be many who think Genic Co., Ltd.'s ( KOSDAQ:123330 ) price-to-sales (or "P/S") ratio of 0.8x is worth a...
Analysis Article Mar 12

Genic Co., Ltd.'s (KOSDAQ:123330) Shareholders Might Be Looking For Exit

With a median price-to-sales (or "P/S") ratio of close to 1x in the Personal Products industry in Korea, you could be...
Analysis Article Mar 19

Genic (KOSDAQ:123330) Is Making Moderate Use Of Debt

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysis Article Dec 03

We Think Genic (KOSDAQ:123330) Has A Fair Chunk Of Debt

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Genic has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

KOSDAQ:A123330 - Analysts future estimates and past financials data (KRW Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202578,19818,88717,96720,651N/A
9/30/202585,47218,30412,12114,743N/A
6/30/202577,04814,9186,4968,760N/A
3/31/202561,37311,7073,3895,119N/A
12/31/202449,9087,563-1,379272N/A
9/30/202436,668-144-2,203-1,448N/A
6/30/202428,940-2,369-1,651-1,443N/A
3/31/202428,133-4,229-1,503-1,030N/A
12/31/202328,070-4,411-1,110-268N/A
9/30/202328,690-4,695-1,689-290N/A
6/30/202329,902-2,556-2,292-577N/A
3/31/202329,944-1,805-1,170642N/A
12/31/202231,449-3,340-1,237186N/A
9/30/202233,167-3,7211821,113N/A
6/30/202233,525-6,2491,0601,982N/A
3/31/202235,849-6,860-270289N/A
12/31/202138,408-4,1991,9192,570N/A
9/30/202139,846-1,764-2585N/A
6/30/202139,067-1,9472,2462,560N/A
3/31/202140,319-1181,7882,624N/A
12/31/202042,13231-563213N/A
9/30/202042,074-1,465-1,047-56N/A
6/30/202045,428398-1,593-451N/A
3/31/202044,5765294251,164N/A
12/31/201943,151-7125011,377N/A
9/30/201949,666-2,911N/A2,878N/A
6/30/201954,155-8,526N/A-5,363N/A
3/31/201960,514-15,562N/A-11,146N/A
12/31/201869,027-15,323N/A-8,903N/A
9/30/201868,872-14,092N/A-9,411N/A
6/30/201868,200-11,975N/A-5,808N/A
3/31/201865,889-6,965N/A-691N/A
12/31/201764,690-7,467N/A-4,087N/A
9/30/201764,376-6,277N/A-2,998N/A
6/30/201768,865-2,864N/A-683N/A
3/31/201787,880-686N/A713N/A
12/31/201689,6681,225N/A1,925N/A
9/30/201694,2293,654N/A4,267N/A
6/30/201694,2803,263N/A3,890N/A
3/31/201675,3732,700N/A2,243N/A
12/31/201573,7062,925N/A3,764N/A
9/30/201571,1724,476N/A4,901N/A
6/30/201567,4794,265N/A5,735N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if A123330's forecast earnings growth is above the savings rate (3.1%).

Earnings vs Market: Insufficient data to determine if A123330's earnings are forecast to grow faster than the KR market

High Growth Earnings: Insufficient data to determine if A123330's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if A123330's revenue is forecast to grow faster than the KR market.

High Growth Revenue: Insufficient data to determine if A123330's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if A123330's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/20 07:59
End of Day Share Price 2026/05/20 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Genic Co., Ltd. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Eun Jung ParkDaishin Securities Co. Ltd.
Na Young ParkDaiwa Securities Co. Ltd.
Choi Soon-HoEugene Investment & Securities Co Ltd.